This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sanofi (SNY) Q2 Earnings In Line, Sales Lag,'17 View Raised
by Zacks Equity Research
Sanofi (SNY) Q2 results were mixed as it reported in-line earnings and slightly missed sales expectations. However, the company raised its 2017 earnings guidance.
Company News For July 31, 2017
by Zacks Equity Research
Companies in the news are: EXPE,MRK,ALGN,MAT
The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck and Co., McDonald's, Caterpillar and The Boeing Company
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck and Co., McDonald's, Caterpillar and The Boeing Company
Dow 30 Stock Roundup: Caterpillar, DuPont, MCD, P&G Beat
by Swarup Gupta
The Dow enjoyed a strong week of gains, riding on stellar earnings results.
AstraZeneca (AZN) Beats on Q2 Earnings, Falls on Failed Study
by Zacks Equity Research
AstraZeneca PLC (AZN) reported second-quarter 2017 core earnings of 87 cents per ADS, which beat the Zacks Consensus Estimate of 41 cents. Failure in lung cancer study on Imfinzi however pulled the stock down.
Q2 GDP In Focus
by Zacks Equity Research
Q2 GDP In Focus
Q2 GDP Lands at 2.6%, 1st Read
by Mark Vickery
Q2 Gross Domestic Product (GDP) growth ratcheted up to 2.6%, putting the U.S. economy in 2017 pretty much exactly where we expected it: +2%.
4 Drug Stocks in Focus this World Hepatitis Day
by Arpita Dutt
Does the hepatitis C virus (HCV) market still hold potential for companies like Gilead (GILD)?
Merck (MRK) Q2 Earnings & Sales Top on Strong Keytruda Sales
by Zacks Equity Research
Merck & Co. Inc. (MRK) beat estimates for both earnings and sales in the second quarter.
Friday's Earnings Reports To Watch: XOM, CVX, MRK, ABBV
by Jeffrey Hymen
The Zacks Earnings Calendar lists each company that is expected to report earnings on any given calendar date, making it a useful organizational tool for any investor.
Pharma Stocks to Watch for Earnings on Jul 28: ABBV, MRK
by Zacks Equity Research
Total earnings for these 171 index members were up 8.8% from the year-ago quarter on a 3.4% improvement in revenues. Let's see how things are shaping up for the announcements.
Key Takeaways from Lilly's (LLY) Q2 Call: Baricitinib, Cancer Pipeline
by Arpita Dutt
Why were Lilly's (LLY) shares down despite the company delivering a "beat and raise" quarter?
Is a Beat in Store for Agenus (AGEN) this Earnings Season?
by Zacks Equity Research
Agenus Inc. (AGEN) will focus on the development of all its pipeline drugs as currently there are no marketed drug in its portfolio.
Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs
by Sweta Killa
Though the healthcare sector is expected to post an earnings decline and has a dismal Rank, some surprises may well be in the cards, suggesting upside for healthcare ETFs.
What's in the Offing for Bristol-Myers (BMY) in Q2 Earnings?
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Jul 27, before the opening bell. Last quarter, the company beat earnings estimates by 16.7%.
Can Merck (MRK) Pull Off a Surprise this Earnings Season?
by Zacks Equity Research
Merck & Co., Inc.'s (MRK) new products like Keytruda, Zepatier and Bridion are likely to drive sales in Q2. However, headwinds remain in the form genericization of key drugs and increasing competition.
Ligand Signs Agreement with Amgen, Grants Rights to Captisol
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) announced that it has signed a commercial license and supply agreement with Amgen Inc. granting exclusive worldwide rights to use Ligand's Captisol technology for the development of AMG 330
J&J (JNJ) Beats on Q2 Earnings, Lags Sales, Ups 2017 View
by Zacks Equity Research
Johnson & Johnson (JNJ) reported mixed second-quarter 2017 results. While earnings beat expectations, sales missed the same.
Amgen (AMGN) Gets CRL for Osteoporosis Drug Evenity's BLA
by Zacks Equity Research
Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that the FDA has issued a complete response letter (CRL) for the biologics license application (BLA) for Evenity (romosozumab).
The Zacks Analyst Blog Highlights: Facebook, Verizon, Merck, Pepsi and HCA Healthcare
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Verizon, Merck, Pepsi and HCA Healthcare
Gilead (GILD) Application for HIV Drug Validated in EU
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announced that the company's Marketing Authorization Application for once-daily single tablet for the treatment of HIV-1 infection in adults has been fully validated by the European Medicines Agency.
Gilead (GILD) Application for HIV Drug Validated in EU
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announced that the company's Marketing Authorization Application for once-daily single tablet for the treatment of HIV-1 infection in adults has been fully validated by the European Medicines Agency.
The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals
5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates
by Zacks Equity Research
The NYSE ARCA Pharmaceutical Index has risen almost 9.8% year to date.
5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings
by Arpita Dutt
Here is a look at 5 pharma and biotech stocks including Merck (MRK) that are expected to post a positive earnings surprise in Q2.